

5 SENSI PER DIAGNOSI RARE

Opzioni terapeutiche dopo la diagnosi

Di Piercarlo Salari

Bibliografia citata e di approfondimento

PFIC e odeixibat

- Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz Ö, Fischler B, Gonzalès E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Özen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P. Odeixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. *Lancet Gastroenterol Hepatol*. 2022; 7:830-842
- Baumann U, Sturm E, Lacaille F, Gonzalès E, Arnell H, Fischler B, Jørgensen MH, Thompson RJ, Mattsson JP, Ekelund M, Lindström E, Gillberg PG, Torfgård K, Soni PN. Effects of odeixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. *Clin Res Hepatol Gastroenterol*. 2021; 45:101751
- Thompson RJ, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Di Giorgio A, Durmaz Ö, Gonzalès E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Lacaille F, Lachaux A, Lainka E, Loomes KM, Mack CL, Mattsson JP, McKiernan P, Ni Q, Özen H, Rajwal SR, Roquelaure B, Shteyer E, Sokal E, Sokol RJ, Soufi N, Sturm E, Tessier ME, van der Woerd WL, Verkade HJ, Vittorio JM, Wallefors T, Warholc N, Yu Q, Horn P, Kjems L. Interim results from an ongoing, open-label, single-arm trial of odeixibat in progressive familial intrahepatic cholestasis. *JHEP Rep*. 2023; 5:100782 (PEDFIC 2)
- McKiernan P, Bernabeu JQ, Girard M, Indolfi G, Lurz E, Trivedi P. Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis. *JHEP Rep*. 2023; 6:100949
- Verkade HJ, Thompson RJ, Arnell H, Fischler B, Gillberg PG, Mattsson JP, Torfgård K, Lindström E. Systematic Review and Meta-analysis: Partial External Biliary Diversion in Progressive Familial Intrahepatic Cholestasis. *J Pediatr Gastroenterol Nutr*. 2020; 71:176-183
- Di Giorgio A, Sciveres M, Fuoti M, Calvo P, Cananzi M, Lleo A, Gatti S, Indolfi G, Madeo A, Mandato C, Nuti F, Zanchi C, Carioli G, Ghirardi A, Nicastro E, D'Antiga L. Real-world experience with odeixibat in children with progressive familial intrahepatic cholestasis. *JHEP Rep*. 2024; 7:101309

- Bylvay®, RCP

XLH e burosumab

- Carpenter TO, Whyte MP, Imel EA, Boot AM, Högl W, Linglart A, Padidela R, Van't Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA. Burosumab Therapy in Children with X-Linked Hypophosphatemia. *N Engl J Med*. 2018; 378:1987-1998
- Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högl W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. *Lancet*. 2019; 393:2416-2427
- Baroncelli GI, Grandone A, Aversa A, Sessa MR, Pelosini C, Michelucci A, Toschi B, Manca M, Isola A, Comberiati P. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets. *Eur J Med Genet*. 2024; 70:104958
- Sandy JL, Biggin A, Siafarikas A, Simm PJ, Rodda CP, Munns CF. X-Linked Hypophosphataemia and Burosumab: A Systemic Disease With a New Treatment. *J Paediatr Child Health*. 2025; 61:685-700
- Crysvita®, RCP

PH1 e lumasiran

- Michael M, Harvey E, Milliner DS, Frishberg Y, Sas DJ, Calle J, Copelovitch L, Penniston KL, Saland J, Somers MJG, Baum MA. Diagnosis and management of primary hyperoxalurias: best practices. *Pediatr Nephrol*. 2024; 39:3143-3155
- Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnav AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. *N Engl J Med*. 2021; 384:1216-1226
- Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y; ILLUMINATE-B Workgroup. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. *Genet Med*. 2022; 24:654-662

- Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. *Pediatr Nephrol.* 2023; 38:1075-1086
- Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. *Am J Kidney Dis.* 2023; 81:145-155.e1
- Oxlumo®, RCP